SCHEDULE: T. Rowe Price Discloses 7% Stake in Black Diamond Therapeutics

T. Rowe Price Investment Management, Inc. has reported beneficial ownership of 7.0% of Black Diamond Therapeutics' common stock as of June 30, 2026.

Summary

• T. Rowe Price Investment Management, Inc. has filed a Schedule 13G, indicating it beneficially owns 4,028,202 shares of Black Diamond Therapeutics' common stock.
• This holding represents 7.0% of the class of securities.
• The filing specifies sole voting power for 3,992,774 shares and sole dispositive power for 4,028,202 shares.
• The reporting person certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.
• T. Rowe Price Investment Management, Inc. expressly denies beneficial ownership of the securities for the purpose of this filing.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While institutional ownership can be positive, the explicit denial of beneficial ownership by T. Rowe Price tempers any strong positive sentiment.

Positives

• Significant institutional ownership by a reputable investment firm like T. Rowe Price can be seen as a positive signal of confidence in the company's long-term prospects.
• The filing indicates T. Rowe Price has sole dispositive power over the shares, suggesting a clear investment strategy.

Negatives

• The explicit denial of beneficial ownership by T. Rowe Price Investment Management, Inc. may suggest a nuanced or passive investment approach, potentially limiting its influence on corporate strategy.
• The filing does not provide details on the investment thesis or rationale behind acquiring this stake.

Risks

• The filing does not explicitly mention any risks.
• However, as with any investment, the value of Black Diamond Therapeutics' common stock is subject to market fluctuations and company-specific performance risks.

Future Outlook

The filing does not contain forward-looking statements or guidance from the company. It solely reports on T. Rowe Price's ownership stake.

Management Comments

• T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

Industry Context

StockSavvy.ai notes that institutional filings like this Schedule 13G are common in the biotechnology sector, reflecting active portfolio management by investment firms. The 7.0% stake by T. Rowe Price indicates a notable position in Black Diamond Therapeutics.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor's stake, which may influence market perception and trading activity.
• Management: The presence of a substantial institutional holder like T. Rowe Price may lead to increased scrutiny and engagement regarding corporate strategy and performance.

Next Steps

• Monitor future filings from T. Rowe Price Investment Management, Inc. for any changes in their stake.
• Observe Black Diamond Therapeutics' corporate actions and performance for potential impact on institutional investor sentiment.

Key Dates

Keywords

Schedule 13G, Black Diamond Therapeutics, T. Rowe Price Investment Management, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing